{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-046183","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2023-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.636181+00:00","generated_at":"2026-06-07T06:54:12.959633+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Matinas reports oral LNC-oligonucleotides show TNFα reduction in colitis model; psoriasis markers improve","bullets":["Orally LNC-formulated small oligonucleotide targeting TNFα reduced serum TNFα by 37% in DSS-induced colitis model.","Active LNC formulation significantly improved clinical disease activity scores at key time points in colitis study.","In IMQ-induced psoriasis model, LNC-delivered IL-17A oligonucleotide lowered skin tissue IL-17A mRNA and improved redness/scaling.","Plans to present additional tissue/histologic analyses at future scientific meetings.","CEO highlights potential for oral delivery of extra-hepatic small oligonucleotides as differentiating platform feature."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-046183","json":"https://secwatch.observer/filing/0001493152-23-046183.json","markdown":"https://secwatch.observer/filing/0001493152-23-046183.md","text":"https://secwatch.observer/filing/0001493152-23-046183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223046183/0001493152-23-046183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315223046183/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:54:12.959633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}